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Abstract: Introduction: Research into the long-term effects of coronavirus disease 2019 (COVID-19)
continues at an unprecedented pace. Many physical long-term symptoms of COVID-19 have been
reported and include headache, fatigue, muscle pain and breathlessness, etc. Psychological effects are
not dissimilar to survivors of SARS. There is limited qualitative research exploring the mental health
impacts and experiences of hospitalized COVID-19 inpatients. Methods: A prospective qualitative
study is planned to explore patient experiences post hospital discharge following a diagnosis of
COVID-19. The research aims to gain an understanding of how COVID-19 affects quality of life
(QoL) and functional abilities. Patients discharged from the hospital will be invited to take part in
semi-structured interviews discussing their experiences of hospitalization and the impact of COVID-
19 on their QoL. Interviews will be conducted at three and six months following discharge from
hospital. This study will provide important qualitative insight and may inform clinical interventions
and commissioning decisions. Trial registration: The study has Research Ethics Committee (REC)
and Health Research Authority (HRA) approvals obtained from Health and Care Research Wales
(HCRW) [IRAS project ID 293196].
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1. Introduction
The World Health Organization (WHO) declared Coronavirus 2019 (COVID-19), the
multisystem disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), as a pandemic on 11 March 2020 [1]. Commonly presenting symptoms are fever,
cough, breathlessness and fatigue [2]. Individuals older than 60 years of age with comor-
bidities, such as cardiovascular disease, diabetes, hypertension and chronic obstructive
pulmonary disease (COPD), are at the highest risk of severe COVID-19 and death [3]. At the
time of writing, it is estimated that 185,125,237 people have had COVID-19, and 4,002,924
have died from COVID worldwide [4]. Approximately 20% of those with COVID-19 are
estimated to need hospitalization [1]. Of those admitted to hospital, depending on age,
frailty and co-morbidities, mortality can be as high as 95%. Approximately 17% require
admission to high dependency or intensive care units and survival in these sub-groups can
be as low as 28% [5]. The length of inpatient stay with COVID-19 may depend on higher
levels of care and on severity of illness [6].
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The constellation of persisting signs and symptoms (typically longer than 12 weeks),
which can encompass headache, fatigue, muscle pain and breathlessness, has been termed
‘Post COVID Syndrome’ or ‘Long COVID’ [7]. Patients have described symptoms lasting
weeks to months, with up to 87% of previously hospitalized patients being affected in
some cohorts [8,9]. Fatigue, dyspnoea, joint pain and chest pain are commonly reported,
and 40% of patients report a worsened quality of life (QoL) [9]. Those who have been
discharged from intensive care may have significant long-lasting sequelae. Halpin et al. [10]
reported that new illness-related fatigue was the most commonly reported symptom of
patients discharged from the ICU following a COVID-19 diagnosis (72%), followed by
breathlessness (65.5% of ICU patients and 42.6% of ward patients) and psychological
distress (46.9% in ICU patients and 23.5% of ward patients). Their results also indicated
a significant drop in quantitatively measured QoL (68.8% of ICU patients and 45.6% in
ward patients). Huang et al. [11] reported similar findings with approximately two thirds
of patients reporting fatigue and muscle weakness, a quarter reporting sleep difficulty and
a quarter reporting anxiety and depression six months after hospital discharge.
Research into the in-hospital experiences of patients with COVID-19 is limited. In-
ferences can be made from the 2003 severe acute respiratory syndrome (SARS) outbreak.
Patients surviving SARS reported several psychiatric morbidities including persistent
depression, anxiety, panic attacks, psychomotor excitement, psychotic symptoms, delirium
and suicidal ideation [12,13]. The mental health status of patients whilst hospitalized
with COVID-19 suffers: 45.9% had symptoms of depression, 38.8% had anxiety and 54.1%
had insomnia. Greater self-perceived illness severity was significantly associated with
increased symptoms of low mood and anxiety [14]. Additionally, patients admitted to
hospital with COVID-19, a potentially fatal disease, may experience fear resulting in in-
creased anxiety [15]. Due to the risks of disease transmission, patients with COVID-19
often need to be isolated in rooms or wards within the hospital. In the United Kingdom
(UK), this isolation has often been compounded by visiting restrictions; contact with family
members or friends usually limited to telephone or video calls unless the patient was
approaching end of life. Such isolation instills boredom, loneliness and irritability [16].
It is well documented that a lack of socialization can result in depression, anxiety and
exacerbate physical health conditions [17]. R Boyes discloses that, following a five-week
hospital stay, which included mechanical ventilation, he found living independently a
struggle, and reported symptoms of insomnia, memory loss and a sense of abandonment
from medical professionals [18]. While physical recovery is the primary aim during hospi-
talization, the psychological impact and quality of life of patients post discharge must thus
not be overlooked.
Quantitative research can enable an objective understanding of patient experiences,
however, qualitative methods enable a meaningful understanding of an individual’s
thoughts, emotions, attitudes and lived reality of their experiences. Thus, we have set out to
explore patient experiences of being hospitalized with COVID-19 using qualitative research.
2. Materials and Methods
2.1. Study Design
The study is qualitative and phenomenological: patients surviving hospitalization
for COVID-19 will be invited to take part in two semi-structured interviews (three and six
months post-discharge from hospital). A qualitative design will ensure rich in-depth data
are obtained regarding patient’s experiences.
Aims and Objectives
• To understand the experiences of patients who have been hospitalized with COVID-19;
• To understand the impact of COVID-19 on patients’ QoL;
• To understand longer-term impacts of COVID-19 on patients QoL to guide the devel-
opment of appropriate interventions and services to meet the needs of patients.
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2.2. Participants
Inclusion criteria are:
• Patients aged ≥18 years hospitalized with COVID-19 (polymerase chain reaction
[PCR] swab positivity for SARS-CoV-2 and a clinical diagnosis of COVID-19 according
to the admitting medical team;
• Discharged from hospital;
• Ability to provide informed consent;
• Willingness to take part in the interviews over the phone or by video call;
Exclusion criteria are:
• Inability to give informed consent.
Previous research into sample sizes in qualitative research has suggested gaining
participants and interviews until the data analysis and transcription reaches saturation.
Saturation has been found to come at different sample sizes depending on the research aims
and objectives. It has been suggested that, if the qualitative research has specific research
question and aims, little new information is generated after the twelfth interview. The re-
search suggests that if the sample is more heterogenous, saturation may be researched with
a larger sample [19]. Therefore, semi-structured interviews will be conducted until data
saturation is reached. Patients will take part in one semi-structured interview conducted
over the telephone in the comfort of their own home.
2.2.1. Sampling Technique and Identification
The clinical team will identify eligible participants and provide the research team with
the participant’s details. Following eligibility confirmation, a study pack containing an
invitation letter and participant information sheet will the posted to potential participants.
The researcher will telephone the potential participant within seven days to discuss the
study in more detail and allow time to ask questions. For those potential participants
requiring more time to consider participation, a follow-up telephone call will be scheduled
for the following week. Additionally, patients can be identified prospectively by the clinical
team. For those who are identified prospectively, the clinical team will have the option
to provide the patient with a participation information sheet or the researcher will post a
study pack; thereafter, participation will be followed up by the research team.
2.2.2. Consent
Participants have the option to complete witnessed consent or postal consent.
Witnessed consent: the researcher will read the statements on the consent form to the
participant for their verbal agreement, with the participant, the researcher and a witness for
the researcher present. The consent form will be signed by the researcher and the witness.
Postal consent: the researcher will post a consent form to the participant and a call
will be scheduled in for the following week. The researcher will talk the patient through
the consent form and the form will be signed by the patient. The researcher will then
document the patient’s name, and the date and time of the consent call. The patient will
return the original completed consent form to be signed by a member of the research team.
There will be a discrepancy in dates between the patient and researcher signatures.
2.3. Study Interventions
Following consent, the researcher will contact the patient to arrange a convenient time
and date to conduct the telephone/video interview. The patient will be interviewed in
the comfort of their own home, and the interviews will last no longer than one hour (See
Appendix A for interview schedule). Verbal consent will be obtained prior the interviews
to re-confirm that the patient is happy to be interviewed (See Figure 1). Interviews will be
audio-recorded and destroyed once transcribed verbatim. Patients’ demographic details
will be obtained along with the virus strain and whether the patient has been vaccinated.
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Figure 1. Recruitment and Data collection Pathway.
2.4. Risk of Bias
To avoid the risk of researcher bias, all interviews will be transcribed verbatim and
will be reviewed and analyzed by more than one researcher. All themes and subthemes
identified will be agreed upon by all researchers. All participants will be asked the same,
open ended questions and the interviewer will not provide any information regarding
the hospital treatment of the patient prior to the interview. To reduce recruitment bias, all
participants will be asked to pick a convenient time for their interview, including evenings
and weekends. Additionally, adults of all ages are able to take part in the research interview.
2.5. Patient and Public Involvement
Patients have been asked to comment on the acceptability of the research and give
feedback on the Participant Information Sheet. A group will also be invited to review the
results and discuss dissemination of study findings.
2.6. Data Analysis
Thematic Analysis will be used to analyze the transcripts. Thematic analysis is a form
of qualitative research that aims to gather an understanding of a certain phenomenon from
taking common themes from a larger body of data. It has been widely used in research
regarding health and wellbeing to learn from the experiences of others [20]. Interviews
will be read and re-read to ensure familiarization whilst documenting initial codes through
identifying interesting features of the data; once codes are established, they will be collated
into potential themes. The relevant quotations will be reviewed, and the final themes will
be generated. To ensure inter-rated reliability, data will be analyzed by two researchers
independently and interpretations of themes will be shared and discussed to agree upon
key themes that have emerged from the data.
2.7. Approvals
Ethical approval has been granted by Health and Care Research Wales (HCRW) [IRAS
project ID 293196] prior to data collection in a National Health Service (NHS) secondary
care setting and Caldicott approval has been granted [C3713].
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All patients will be assigned a pseudonym to protect their identity and maintain confi-
dentiality. The study will exclude individuals who do not have capacity to consent. Should
an individual lose consent during the ‘active’ period of this study, then the participant will
be withdrawn at that point. Permission to retain data gathered before loss of capacity is
included in the participant consent form. Participants will have the right to withdraw at
any time without a reason and it will be explained that the data collected up to the point of
withdrawal will not be used unless they give their consent.
2.7.1. Data Handling and Storage
For those participants who provide postal consent, the participants name will be kept
only on the consent forms. The name will only be available to the research team and will
not be used in any scientific reports. The data will not be shared with third parties. The
consent forms will be stored in a lockable cabinet, separate from any results of the study.
Electronic data will be stored on a password-protected trust computer server with data
encryption and automated back-up.
2.7.2. Adverse Events
We envisage no risk to the patients; however, if new issues are identified during the
study, the research team will notify the clinical team. Patients will provide consent for the
researcher to notify the clinical team.
If any participant were to disclose risk to themselves or others, as well as possible safe-
guarding concerns, the relevant risk management procedure would be implemented. The
participants will be made aware that their information and data will be kept anonymous;
however, if they were to disclose any harm to themselves or others then information will
be shared amongst professionals and the correct support offered to the participant.
3. Results
Results will be published in peer reviewed journals and presented at national conferences.
4. Conclusions
We hope that adding patients’ voices via this study will increase our understanding
of COVID-19 and its effects. Expected limitations are that this study might take several
months to achieve recruitment and full analysis, that no formal result verification of the
data is possible (as the participants have control over the content of the data) and that
inferring causality might not be possible. Further discussion is beyond the scope of this
protocol paper.
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Appendix A
Table A1. Interview Questions.
Interview Questions
(1) Could you tell me about your experience of being on a hospital ward whilst having a
diagnosis of COVID-19?
(2) How did you feel being admitted to hospital with a COVID-19 diagnosis?
(3) How long was your stay?
(4) Do you feel this was the correct length of stay/do you feel this should have been
shorter/longer?
(5) Can you describe your treatment?
(6) What could have been done differently?
(7) How would you describe your overall experience?
(8) How would you describe your emotional wellbeing during your hospital stay?
(9) How satisfied overall are you with the care and treatment you received?
(10) How have you felt since your discharge from hospital?
(11) How do you feel your life has been impacted following discharge?
(12) How are you managing with your day to day activities?
(13) Are these any different to before you were admitted to hospital?
(14) What are your experiences of managing your self-care now?
(15) How has this changed compared to before your hospital stay?
(16) Have you had to make any changes regarding your personal hygiene?
(17) Have you experienced any long-term symptoms?
(18) Is there anything that you now struggle with that you didn’t before?
(19) How have you felt overall in regards to the social restrictions of COVID-19 and how has this
impacted on your life?
(20) How have you felt in terms of your emotional wellbeing since your discharge?
(21) Have you had to make any adaptations to your daily routine?
(22) Have you had any extra support/care packages put in place following your hospital stay?
(23) Is there anything you feel has specifically changed following your hospital stay?
(24) Is there else you would like to know about your quality of life following discharge?
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